Surgery Partners

Surgery Partners, Inc. is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services, Ancillary Services, and Optical Services. The Surgical Facility Services segment consists of the operation of ambulatory surgery centers and surgical hospitals, including anesthesia services of the company. The Ancillary Services segment operates a diagnostic laboratory and multi-specialty physician practices. The Optical Services segment involves an optical laboratory and an optical products group purchasing organization. The company was founded in 2004 and is headquartered in Brentwood, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Surgery Partners reports robust Q4 earnings, eyes growth in cardiac care

Surgery Partners' strong financial performance, driven by strategic initiatives and revenue growth, positions the company for continued success. While facing challenges in adoption rates and reimbursement, the company's focus on outpatient care and higher acuity service lines presents growth opportunities. With a proactive approach to recruitment and expansion, Surgery Partners is poised for a positive trajectory in 2023.

Surgery Partners (SGRY) posts robust Q1 results, eyes strategic growth

Surgery Partners (SGRY) delivered strong financial performance, operational efficiency, and strategic growth initiatives in Q1 2023.
Despite challenges from revenue timing and minimal earnings impact in the short term, the company's disciplined approach and focus on partnerships and acquisitions offer promising opportunities.
With a raised adjusted EBITDA outlook, a commitment to excellence, and a clear growth strategy, Surgery Partners is well-positioned for continued success and value creation.

Surgery Partners exceeds Q2 expectations, eyes strategic growth opportunities

Surgery Partners delivered strong financial performance in Q2 2023, surpassing expectations and demonstrating resilience in surgical case growth.
Despite challenges in anesthesia coverage and subsidies, the company remains optimistic about its growth prospects and is focused on operational efficiencies.
Strategic investments in orthopedics and cardiology, along with a commitment to high-quality care, underscore Surgery Partners' long-term growth potential.

Surgery Partners beats Q3 targets, eyes mid-teens growth in 2024

Surgery Partners exceeded Q3 expectations, showcasing strong performance and strategic initiatives. While facing challenges from portfolio adjustments and regulatory proposals, the company is well-positioned for continued growth through acquisitions and focus on high acuity cases.

Surgery Partners (SGRY) reports robust 2023 results and eyes strategic growth in 2024

Surgery Partners (SGRY) delivered strong financial performance in 2023, with a positive outlook for 2024. The company's focus on margin expansion, growth in higher acuity procedures, and strategic acquisitions positions it well for continued success. Challenges include cash flow uncertainties and the impact of unique comp dynamics on case growth.

Surgery Partners (SGRY) reports robust Q1 earnings and eyes strategic acquisitions for continued growth

Surgery Partners (SGRY) delivered strong financial results in Q1 2024, showcasing solid revenue growth and margin expansion. The company's strategic focus on acquisitions, margin improvement initiatives, and effective cost management underpin its optimistic outlook for sustained growth and cash flow generation.

Surgery Partners (SGRY) posts impressive Q2 results, raises full-year outlook

Surgery Partners (SGRY) delivered strong financial performance in Q2 2024, driven by revenue growth, enhanced margins, and strategic acquisitions. Despite facing leverage challenges, the company's focus on specialty physician recruitment and operational efficiency presents opportunities for sustained growth and profitability.

Surgery Partners posts strong Q3 results amidst Hurricane challenges

Surgery Partners demonstrated robust financial performance in Q3 2024, marked by revenue growth, margin expansion, and strategic acquisitions.
While facing challenges from Hurricane Helene, the company's focus on recruitment and growth in key specialties positions it well for future success.
With a strong outlook for the full year and a focus on high-growth markets and specialties, Surgery Partners shows resilience and strategic foresight.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Surgery Partners, Inc. (NASDAQ:SGRY ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Dave Doherty - Chief Financial Officer Wayne DeVeydt - Executive Chairman Eric Evans - Chief Executive Officer Conference Call Participants Jack Slevin - Jefferies Joanna Gajuk - Bank of America A.J. Rice - UBS Andrew Mok - Barclays Tao Qiu - Stifel Sarah James - Cantor Fitzgerald Bill Sutherland - The Benchmark Company Benjamin Rossi - JPMorgan Will Spivack - TD Cowen Operator Greetings, and welcome to the Surgery Partners Third Quarter 2024 Earnings Call.

Surgery Partners, Inc. (SGRY) Q3 2024 Earnings Call Transcript

Surgery Partners (SGRY) came out with quarterly earnings of $0.19 per share, missing the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.19 per share a year ago.

Surgery Partners (SGRY) Misses Q3 Earnings Estimates

Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Surgery Partners (SGRY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BRENTWOOD, Tenn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its third quarter 2024 results before the market opens on Tuesday, November 12, 2024, to be followed by a conference call at 8:30 a.m. (Eastern Time).

Surgery Partners, Inc. Announces Third Quarter 2024 Earnings Release Date and Conference Call Details

With the stock markets trading near highs again and the start of a lower interest rates cycle, the backdrop for mergers, spin-offs, and acquisitions continues to improve. Elevated stock prices are just as good as currency when trying to acquire another company.

Here's Why Surgery Partners Could Be the Next Hot Takeover

CHICAGO--(BUSINESS WIRE)--Oral Surgery Partners (“OSP”), an established oral surgery management group, is pleased to announce the appointment of Sohail Malad as its new Chief Executive Officer, effective August 12th. Sohail Malad, a seasoned healthcare executive with a proven track record of leadership and innovation, will succeed John Cline, who served as CEO for the past three years and will continue to remain involved in an advisory capacity. Under John's tenure, OSP experienced significant.

Sheridan Capital Partners-Backed Oral Surgery Partners Announces Appointment of New CEO

Surgery Partners (SGRY) came out with quarterly earnings of $0.21 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.28 per share a year ago.

Surgery Partners (SGRY) Meets Q2 Earnings Estimates

BRENTWOOD, Tenn., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the second quarter ended June 30, 2024.

Surgery Partners, Inc. Announces Second Quarter 2024 Results Raises Full Year 2024 Guidance

Investors looking for stocks in the Medical Services sector might want to consider either Surgery Partners (SGRY) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?

SGRY or MEDP: Which Is the Better Value Stock Right Now?

BRENTWOOD, Tenn., July 16, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its second quarter 2024 results before the market opens on Tuesday, August 6, 2024, to be followed by a conference call at 8:30 a.m. (Eastern Time)

Surgery Partners, Inc. Announces Second Quarter 2024 Earnings Release Date and Conference Call Details

Medpace Holdings

Investors interested in stocks from the Medical Services sector have probably already heard of Surgery Partners (SGRY) and Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?

SGRY vs. MEDP: Which Stock Is the Better Value Option?

The mean of analysts' price targets for Surgery Partners (SGRY) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Surgery Partners (SGRY) Could Surge 57.53%: Read This Before Placing a Bet

CHICAGO--(BUSINESS WIRE)--Oral Surgery Partners (“OSP”) announced today the closing of a $75 million credit expansion. The facility expansion was provided by the existing lending partners and will allow OSP to continue to grow through 2024 and beyond. “OSP's lenders continue to show strong support for the company due to its well-established track record and continued performance. We're excited to have like-minded lending partners who share the vision of providing excellent care in oral surgery.

Sheridan Capital Partners-Backed Oral Surgery Partners Announces $75M Credit Expansion

Surgery Partners, Inc. (NASDAQ:SGRY ) Q1 2024 Results Conference Call May 4, 2024 8:30 AM ET Company Participants Dave Doherty - Chief Financial Officer Wayne DeVeydt - Executive Chairman Eric Evans - Chief Executive Officer Conference Call Participants Brian Tanquilut - Jefferies Whit Mayo - SVB Leerink Kevin Fischbeck - Bank of America Andrew Mok - Barclays Sarah James - Cantor Fitzgerald Gary Taylor - TD Cowen Bill Sutherland - The Benchmark Company Jason Cassorla - Citi Cal Sternick - JPMorgan Chase Ben Hendrix - RBC Capital Markets Operator Greetings. Welcome to Surgery Partners First Quarter 2024 Earnings Call.

Surgery Partners, Inc. (SGRY) Q1 2024 Earnings Call Transcript

Surgery Partners (SGRY) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.08 per share a year ago.

Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates

BRENTWOOD, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2024.

Surgery Partners, Inc. Announces First Quarter 2024 Results

Earnings Preview: Surgery Partners (SGRY) Q1 Earnings Expected to Decline

BRENTWOOD, Tenn., April 18, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its first quarter 2024 results before the market opens on Tuesday, May 7, 2024, to be followed by a conference call at 8:30 a.m. (Eastern Time).

Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call Details

Doximity

Investors interested in stocks from the Medical Services sector have probably already heard of Surgery Partners (SGRY) and Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks?

SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?

BRENTWOOD, Tenn., March 26, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY)  (“Surgery Partners” or the “Company”) today announced that its wholly-owned subsidiary, Surgery Center Holdings, Inc. (the “Issuer”), priced $800,000,000 aggregate principal amount of its 7.250% senior unsecured notes due 2032 (the “Notes”) in a previously announced private offering exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The offering is expected to close on April 10, 2024, subject to certain customary closing conditions. The Notes will be guaranteed (the “Guarantees”) on a senior unsecured basis by each domestic wholly-owned subsidiary of the Issuer that guarantees its obligations under its senior secured credit facilities.

Surgery Partners, Inc. Announces Pricing of New Senior Notes Offering

BRENTWOOD, Tenn., March 26, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced today that Surgery Center Holdings, Inc., a wholly owned subsidiary of the Company (the “Issuer”), intends to offer, subject to market and other considerations, $600,000,000 aggregate principal amount of senior unsecured notes due 2032 (the “Notes”). The Notes will be guaranteed (the “Guarantees”) on a senior unsecured basis by each domestic wholly-owned subsidiary of the Issuer that guarantees its obligations under its senior secured credit facilities. The terms of the Notes, including interest rate and principal amount, will depend on market conditions at the time of pricing and will be determined by negotiations among Surgery Partners and the initial purchasers of the Notes.

Surgery Partners, Inc. Announces New Senior Notes Offering

Surgery Partners (SGRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Surgery Partners (SGRY) Upgraded to Buy: What Does It Mean for the Stock?

The mean of analysts' price targets for Surgery Partners (SGRY) points to a 39% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Surgery Partners (SGRY) Could Rally 39.04%: Here's is How to Trade

Surgery Partners, Inc. (NASDAQ:SGRY) Q4 2023 Earnings Conference Call February 26, 2024 8:30 AM ET

Surgery Partners, Inc. (SGRY) Q4 2023 Earnings Call Transcript

Amazon

Equitrans Midstream

Microsoft

NVIDIA

Occidental Petroleum

Follow Warren Buffett's latest tips and bet on top-ranked stocks like Microsoft (MSFT), Amazon.com (AMZN), Surgery Partners (SGRY) and Nvidia (NVDA).

News for Surgery Partners Stock (SGRY)